Search
Curis Inc
CRISAdd to Watchlist
5.020USD
+0.060+1.21%
Close 07-31 16:00（ET）Quotes delayed by 15 min
10.03MMarket Cap
LossP/E TTM
More Details of Curis Inc Company
Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). The Erivedge, is a commercialized orally administered small molecule Hedgehog signaling pathway antagonist. Its other clinical programs include Fimepinostat and CA-170. CA-170 is an oral small molecule drug candidate that targets V-domain Ig Suppressor of T-cell Activation, or VISTA, and PDL1 immune checkpoint proteins.
Curis Inc Info
Ticker SymbolCRIS
Company nameCuris Inc
IPO dateAug 01, 2000
CEODentzer (James E)
Number of employees33
Security typeOrdinary Share
Fiscal year-endAug 01
Address128 Spring Street
CityLEXINGTON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02421
Phone16175036500
Websitehttps://www.curis.com/
Ticker SymbolCRIS
IPO dateAug 01, 2000
CEODentzer (James E)
Company Executives of Curis Inc
Name
Name/Position
Position
Shareholding
Change
Mr. James E. Dentzer
Mr. James E. Dentzer
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
7.44K
--
Ms. Diantha Duvall
Ms. Diantha Duvall
Chief Financial Officer
Chief Financial Officer
3.88K
--
Dr. Kenneth I. Kaitin, Ph.D.
Dr. Kenneth I. Kaitin, Ph.D.
Independent Director
Independent Director
70.00
-714.29%
Mr. Martyn D. Greenacre
Mr. Martyn D. Greenacre
Independent Chairman of the Board
Independent Chairman of the Board
65.00
--
Dr. Marc Rubin, M.D.
Dr. Marc Rubin, M.D.
Independent Director
Independent Director
--
--
Dr. John A. Hohneker, M.D.
Dr. John A. Hohneker, M.D.
Independent Director
Independent Director
--
--
Dr. Anne Borgman, M.D.
Dr. Anne Borgman, M.D.
Independent Director
Independent Director
--
--
Dr. Jonathan Zung, Ph.D.
Dr. Jonathan Zung, Ph.D.
Chief Development Officer
Chief Development Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. James E. Dentzer
Mr. James E. Dentzer
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
7.44K
--
Ms. Diantha Duvall
Ms. Diantha Duvall
Chief Financial Officer
Chief Financial Officer
3.88K
--
Dr. Kenneth I. Kaitin, Ph.D.
Dr. Kenneth I. Kaitin, Ph.D.
Independent Director
Independent Director
70.00
-714.29%
Mr. Martyn D. Greenacre
Mr. Martyn D. Greenacre
Independent Chairman of the Board
Independent Chairman of the Board
65.00
--
Dr. Marc Rubin, M.D.
Dr. Marc Rubin, M.D.
Independent Director
Independent Director
--
--
Dr. John A. Hohneker, M.D.
Dr. John A. Hohneker, M.D.
Independent Director
Independent Director
--
--
FAQs
Who are the top five shareholders of Curis Inc?
The top five shareholders of Curis Inc are: Mr. James E. Dentzer
How many institutions hold shares of Curis Inc (CRIS)?
As of 2026Q1, 85 institutions hold shares of Curis Inc, with a combined market value of approximately 9.82M, accounting for 24.60% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 4490399.00.